Subhanu Saxena

Biography

 Cipla is an Indian company with a global point of view. During the long tenure of family scion Y. K. Hamied, Cipla was a vocal advocate for wider use of affordable generics through the reinterpretation of IP rules. Today, under the leadership of a big Pharma veteran, Subhanu Saxena, the company is following a more diversified path to growth, with a portfolio that includes prescription drugs, veterinary medicines, and OTC – 1,600 products in all, sold in more than 150 countries outside India. More important, Cipla is investing heavily in R&D as part of an ambitious therapeutic expansion program covering some 200 new drugs at various stages of development in key areas of unmet demand, including respiratory, oncology and HIV.  And like the rest of the Indian industry, Saxena has his sights on the US market, where the goal is to increase sales – from 10 per cent of overall global sales at present to 25 per cent by 2020 – through organic growth, development partnerships and targeted acquisitions. Pharm Exec European Editor Julian Upton sat down with Saxena at the recent UBM CPhI Global trade show in Madrid for an update on Cipla’s plans to leverage its historic visibility as an emerging market champion to the next level of global leadership in biopharma.       

Research Interest

 Pharmaceutical Industry, Biopharmaceutical, Veterinary Science, oncology and HIV ,Pharmaceutical Sales ,New Business Development, R&D ,Emerging Markets, Strategic Planning, Business Development